| Code | Description | Claims | Beneficiaries | Total Paid |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
574,884 |
509,794 |
$91.39M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
413,654 |
367,386 |
$69.10M |
| G2067 |
Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) |
235,703 |
90,809 |
$47.31M |
| H0020 |
Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) |
870,230 |
109,766 |
$31.32M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
145,168 |
138,414 |
$29.17M |
| 90832 |
Psychotherapy, 30 minutes with patient |
213,317 |
150,860 |
$26.89M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
135,654 |
129,145 |
$26.44M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
124,499 |
118,120 |
$25.47M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
166,900 |
142,747 |
$25.36M |
| 99201 |
|
301,067 |
281,198 |
$20.95M |
| 99215 |
Prolong outpt/office vis |
91,035 |
83,839 |
$17.03M |
| J9271 |
Injection, pembrolizumab, 1 mg |
1,952 |
1,568 |
$16.53M |
| G0396 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes |
119,555 |
70,564 |
$14.72M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
73,057 |
69,631 |
$13.87M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
68,498 |
58,026 |
$11.68M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
6,757 |
3,631 |
$11.24M |
| 90834 |
Psychotherapy, 45 minutes with patient |
63,466 |
39,043 |
$11.20M |
| 80053 |
Comprehensive metabolic panel |
504,368 |
438,504 |
$10.88M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
58,301 |
53,748 |
$10.72M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
165,926 |
155,050 |
$10.67M |
| G0397 |
Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes |
58,520 |
39,389 |
$9.61M |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
129,355 |
122,615 |
$9.25M |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
79,343 |
67,240 |
$5.64M |
| 86850 |
|
137,379 |
122,443 |
$5.15M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
40,108 |
39,948 |
$4.87M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
1,040 |
663 |
$4.80M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
33,321 |
32,690 |
$4.69M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
39,169 |
38,984 |
$4.62M |
| 92551 |
|
55,367 |
54,877 |
$4.59M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
25,490 |
24,982 |
$4.51M |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
2,083 |
903 |
$4.51M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
68,425 |
23,937 |
$4.18M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
28,434 |
28,158 |
$4.16M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
107,030 |
97,513 |
$4.16M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
5,274 |
5,187 |
$3.88M |
| 90791 |
Psychiatric diagnostic evaluation |
17,452 |
17,047 |
$3.87M |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
2,321 |
2,242 |
$3.74M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
24,779 |
16,413 |
$3.53M |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
39,410 |
39,264 |
$3.44M |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
805 |
711 |
$3.40M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
28,430 |
28,107 |
$3.38M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
174,264 |
164,504 |
$3.22M |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
4,645 |
4,603 |
$3.19M |
| 70450 |
Computed tomography, head or brain; without contrast material |
22,281 |
21,876 |
$3.18M |
| 87631 |
|
43,160 |
42,187 |
$3.10M |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
130,339 |
128,840 |
$3.09M |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
27,022 |
26,804 |
$3.07M |
| 96415 |
|
9,285 |
7,600 |
$3.06M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
121,820 |
116,707 |
$3.03M |
| 19318 |
|
1,170 |
988 |
$3.00M |
| 86480 |
|
48,058 |
47,479 |
$2.99M |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
8,941 |
8,904 |
$2.96M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
26,696 |
23,479 |
$2.91M |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
26,201 |
26,005 |
$2.91M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
23,664 |
22,731 |
$2.90M |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
3,806 |
3,736 |
$2.79M |
| 76770 |
|
19,528 |
19,386 |
$2.77M |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
1,863 |
1,855 |
$2.73M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
164,640 |
160,683 |
$2.68M |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
43,243 |
42,004 |
$2.65M |
| 93458 |
|
1,792 |
1,744 |
$2.64M |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
19,674 |
18,785 |
$2.64M |
| 80061 |
Lipid panel |
243,061 |
240,358 |
$2.62M |
| 93970 |
|
12,364 |
12,178 |
$2.62M |
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
1,591 |
937 |
$2.58M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
773 |
597 |
$2.56M |
| H0005 |
Alcohol and/or drug services; group counseling by a clinician |
26,936 |
7,329 |
$2.39M |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
46,303 |
39,836 |
$2.36M |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
5,490 |
4,641 |
$2.27M |
| 77386 |
|
8,833 |
935 |
$2.27M |
| 87536 |
|
26,227 |
25,889 |
$2.23M |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
2,534 |
1,378 |
$2.18M |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
2,387 |
2,361 |
$2.17M |
| 54161 |
|
1,661 |
1,647 |
$2.09M |
| 90836 |
|
19,233 |
12,648 |
$2.09M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12,295 |
12,189 |
$2.07M |
| 77412 |
|
7,190 |
1,141 |
$2.03M |
| 86901 |
|
135,557 |
123,265 |
$1.89M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
9,888 |
9,785 |
$1.86M |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
7,138 |
4,580 |
$1.83M |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
7,820 |
7,761 |
$1.82M |
| 87507 |
|
6,472 |
6,341 |
$1.77M |
| 90686 |
|
85,187 |
84,890 |
$1.75M |
| 36415 |
Collection of venous blood by venipuncture |
151,527 |
139,730 |
$1.74M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
77,958 |
58,586 |
$1.72M |
| 52000 |
|
1,642 |
1,631 |
$1.71M |
| J0897 |
Injection, denosumab, 1 mg |
1,357 |
1,310 |
$1.71M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
5,642 |
5,601 |
$1.68M |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
13,708 |
13,662 |
$1.67M |
| 20610 |
|
6,310 |
5,578 |
$1.65M |
| T1999 |
Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" |
681 |
630 |
$1.63M |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
6,842 |
6,717 |
$1.63M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
42,839 |
33,871 |
$1.63M |
| 59025 |
Fetal non-stress test |
12,356 |
10,211 |
$1.62M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
2,680 |
1,865 |
$1.61M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
68,617 |
50,955 |
$1.60M |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
5,903 |
5,676 |
$1.55M |
| 64483 |
|
1,766 |
1,712 |
$1.50M |
| 51798 |
|
5,954 |
5,821 |
$1.50M |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
27,874 |
26,033 |
$1.49M |
| 86900 |
|
135,605 |
123,306 |
$1.48M |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
80,695 |
78,885 |
$1.48M |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
5,684 |
5,631 |
$1.46M |
| 36512 |
|
1,398 |
1,316 |
$1.45M |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
2,175 |
1,560 |
$1.45M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
642,069 |
581,728 |
$1.43M |
| 99401 |
|
23,111 |
15,622 |
$1.42M |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
14,411 |
14,307 |
$1.40M |
| 81513 |
|
22,153 |
21,710 |
$1.39M |
| J9299 |
Injection, nivolumab, 1 mg |
264 |
169 |
$1.39M |
| D0120 |
Periodic oral evaluation - established patient |
30,745 |
19,247 |
$1.34M |
| 77336 |
|
5,515 |
2,743 |
$1.34M |
| J9306 |
Injection, pertuzumab, 1 mg |
235 |
182 |
$1.30M |
| 93976 |
|
6,303 |
6,192 |
$1.29M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
69,766 |
65,557 |
$1.28M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
10,087 |
9,993 |
$1.27M |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
8,882 |
8,195 |
$1.27M |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
8,747 |
7,426 |
$1.26M |
| 41899 |
Unlisted procedure, dentoalveolar structures |
798 |
786 |
$1.26M |
| 19083 |
|
898 |
883 |
$1.25M |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
6,118 |
6,086 |
$1.25M |
| 83036 |
Hemoglobin; glycosylated (A1C) |
261,197 |
258,674 |
$1.24M |
| 76818 |
|
15,311 |
6,913 |
$1.22M |
| H0004 |
Behavioral health counseling and therapy, per 15 minutes |
17,591 |
13,786 |
$1.20M |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
6,445 |
6,397 |
$1.19M |
| Q5116 |
Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg |
910 |
534 |
$1.17M |
| J3490 |
Unclassified drugs |
34,579 |
24,757 |
$1.17M |
| 87481 |
|
24,219 |
23,718 |
$1.16M |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
37,510 |
37,396 |
$1.10M |
| 92567 |
|
19,089 |
18,878 |
$1.09M |
| 99381 |
|
7,598 |
7,568 |
$1.09M |
| D0150 |
Comprehensive oral evaluation - new or established patient |
17,555 |
7,933 |
$1.07M |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
13,172 |
5,234 |
$1.07M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
1,598 |
1,462 |
$1.04M |
| 87806 |
|
56,645 |
56,101 |
$1.04M |
| 92557 |
|
11,963 |
11,803 |
$1.03M |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
5,907 |
5,878 |
$1.03M |
| 47562 |
|
577 |
569 |
$1.02M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
8,631 |
8,568 |
$1.01M |
| 80076 |
|
60,710 |
59,252 |
$1.00M |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
3,845 |
2,992 |
$1.00M |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
68,506 |
68,015 |
$993K |
| 86359 |
|
24,587 |
23,799 |
$986K |
| 90651 |
|
17,402 |
17,298 |
$982K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
1,828 |
1,809 |
$978K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
10,882 |
10,686 |
$976K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
917 |
698 |
$973K |
| Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
608 |
298 |
$968K |
| 74183 |
|
3,531 |
3,499 |
$963K |
| 64493 |
|
1,224 |
1,073 |
$953K |
| 99385 |
|
8,255 |
8,209 |
$941K |
| 86780 |
|
116,326 |
114,857 |
$927K |
| 90670 |
|
29,200 |
29,154 |
$925K |
| J9312 |
Injection, rituximab, 10 mg |
268 |
162 |
$910K |
| 88142 |
|
39,983 |
39,849 |
$892K |
| J9035 |
Injection, bevacizumab, 10 mg |
206 |
113 |
$878K |
| 71250 |
|
11,311 |
11,217 |
$875K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
4,625 |
4,557 |
$867K |
| 90846 |
Family psychotherapy without the patient present, 50 minutes |
5,521 |
3,684 |
$844K |
| 86360 |
|
24,310 |
23,797 |
$841K |
| 90837 |
Psychotherapy, 53 minutes with patient |
4,511 |
2,735 |
$831K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
62,789 |
56,853 |
$826K |
| H2010 |
Comprehensive medication services, per 15 minutes |
8,517 |
7,494 |
$824K |
| 81243 |
|
8,849 |
8,794 |
$816K |
| 12001 |
|
2,770 |
2,722 |
$808K |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
495 |
478 |
$800K |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
6,893 |
1,256 |
$799K |
| 84443 |
Thyroid stimulating hormone (TSH) |
158,159 |
155,056 |
$797K |
| 76830 |
Ultrasound, transvaginal |
14,423 |
14,277 |
$790K |
| 88342 |
|
10,801 |
10,520 |
$784K |
| 95782 |
|
973 |
878 |
$778K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
169 |
107 |
$771K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
6,342 |
3,715 |
$771K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
3,441 |
3,392 |
$755K |
| 31237 |
|
517 |
437 |
$751K |
| 99243 |
|
3,924 |
3,906 |
$751K |
| J9145 |
Injection, daratumumab, 10 mg |
243 |
89 |
$750K |
| 36430 |
|
6,074 |
4,456 |
$749K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
4,894 |
4,861 |
$749K |
| 90750 |
|
6,399 |
6,356 |
$746K |
| 82728 |
|
84,343 |
81,772 |
$741K |
| 46607 |
|
1,016 |
929 |
$722K |
| 86803 |
|
84,244 |
83,551 |
$722K |
| 96127 |
|
142,051 |
138,174 |
$718K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
9,480 |
8,617 |
$713K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
1,299 |
1,238 |
$710K |
| 90671 |
|
4,689 |
4,688 |
$703K |
| 83655 |
|
54,886 |
54,521 |
$702K |
| 80050 |
General health panel |
32,605 |
32,167 |
$691K |
| 71046 |
Radiologic examination, chest; 2 views |
88,360 |
85,776 |
$690K |
| 81001 |
|
188,523 |
168,268 |
$687K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
80,221 |
78,745 |
$685K |
| V2632 |
Posterior chamber intraocular lens |
13,271 |
2,723 |
$684K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
15,835 |
15,608 |
$681K |
| 12011 |
|
2,364 |
2,323 |
$678K |
| 43235 |
|
815 |
813 |
$676K |
| 99442 |
|
6,647 |
6,260 |
$660K |
| 92134 |
|
8,157 |
7,385 |
$657K |
| 86769 |
|
19,216 |
19,035 |
$656K |
| 95117 |
|
9,803 |
6,217 |
$653K |
| 31231 |
|
5,704 |
5,547 |
$652K |
| 82607 |
|
70,062 |
69,327 |
$652K |
| 83970 |
|
19,779 |
19,169 |
$648K |
| J9041 |
Injection, bortezomib, 0.1 mg |
1,139 |
311 |
$644K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
12,781 |
12,256 |
$639K |
| 62323 |
|
951 |
941 |
$634K |
| 77334 |
|
3,064 |
2,245 |
$631K |
| 10060 |
|
2,837 |
2,737 |
$628K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
16,763 |
16,244 |
$612K |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
597 |
186 |
$607K |
| 90715 |
|
26,666 |
26,580 |
$605K |
| 77066 |
Tomosynthesis, mammo |
6,564 |
6,479 |
$602K |
| 99386 |
|
5,191 |
5,167 |
$599K |
| 83520 |
|
6,246 |
6,082 |
$599K |
| 84439 |
|
103,710 |
101,484 |
$597K |
| 73221 |
|
2,892 |
2,873 |
$591K |
| 81329 |
|
7,722 |
7,614 |
$584K |
| 88307 |
|
3,168 |
3,103 |
$583K |
| D1351 |
Sealant - per tooth |
14,034 |
3,758 |
$580K |
| 72141 |
|
3,156 |
3,138 |
$572K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
602 |
601 |
$572K |
| 20611 |
|
596 |
573 |
$568K |
| 76536 |
|
9,518 |
9,449 |
$567K |
| 86003 |
|
12,345 |
11,592 |
$556K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
20,073 |
9,248 |
$552K |
| 83880 |
|
29,316 |
28,126 |
$547K |
| G2078 |
Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure |
16,764 |
8,817 |
$545K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
12,477 |
11,082 |
$542K |
| 99205 |
Prolong outpt/office vis |
2,646 |
2,613 |
$528K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
18,118 |
17,677 |
$523K |
| 97162 |
|
4,089 |
4,074 |
$516K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
326 |
266 |
$513K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
9,337 |
4,945 |
$504K |
| 72197 |
|
1,483 |
1,471 |
$504K |
| H0001 |
Alcohol and/or drug assessment |
2,457 |
1,815 |
$502K |
| 29881 |
|
646 |
641 |
$496K |
| 99443 |
|
4,620 |
4,198 |
$496K |
| 77300 |
|
1,794 |
1,479 |
$490K |
| 87799 |
|
9,872 |
7,545 |
$487K |
| 93320 |
|
7,697 |
7,505 |
$486K |
| Q5120 |
Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg |
204 |
163 |
$485K |
| 92083 |
|
6,563 |
5,372 |
$476K |
| J2357 |
Injection, omalizumab, 5 mg |
2,676 |
2,243 |
$475K |
| 86832 |
|
2,284 |
2,162 |
$469K |
| 77290 |
|
1,466 |
1,142 |
$469K |
| 74178 |
|
2,897 |
2,881 |
$467K |
| 77065 |
Tomosynthesis, mammo |
7,439 |
7,078 |
$463K |
| 76642 |
|
10,724 |
10,552 |
$461K |
| 83021 |
|
25,758 |
24,128 |
$457K |
| 84466 |
|
60,239 |
58,697 |
$456K |
| 96367 |
|
6,763 |
5,504 |
$448K |
| 81025 |
|
20,974 |
19,614 |
$446K |
| 86833 |
|
2,281 |
2,159 |
$446K |
| 31575 |
|
4,101 |
4,018 |
$445K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
16,897 |
16,856 |
$438K |
| 11900 |
|
1,478 |
1,443 |
$437K |
| H0049 |
Alcohol and/or drug screening |
14,992 |
14,897 |
$436K |
| D1120 |
Prophylaxis - child |
9,898 |
8,162 |
$434K |
| 99383 |
|
3,378 |
3,368 |
$428K |
| 75574 |
|
2,681 |
2,669 |
$416K |
| 0002A |
|
10,945 |
10,943 |
$412K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
4,362 |
2,049 |
$412K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
135,804 |
129,075 |
$411K |
| 99441 |
|
4,432 |
4,213 |
$411K |
| 93325 |
|
9,449 |
9,103 |
$407K |
| 77301 |
|
680 |
599 |
$405K |
| 87497 |
|
12,301 |
8,002 |
$403K |
| 90739 |
|
3,132 |
3,116 |
$401K |
| 90732 |
|
3,920 |
3,903 |
$397K |
| 0001A |
|
12,320 |
12,303 |
$395K |
| 30140 |
|
224 |
204 |
$390K |
| 87490 |
|
51,519 |
49,479 |
$387K |
| C1769 |
Guide wire |
6,321 |
6,167 |
$385K |
| 95250 |
|
1,825 |
1,759 |
$385K |
| 88185 |
|
2,916 |
2,319 |
$383K |
| 93925 |
|
2,138 |
2,092 |
$382K |
| 82803 |
|
14,904 |
13,713 |
$381K |
| J0791 |
Injection, crizanlizumab-tmca, 5 mg |
125 |
64 |
$378K |
| 64615 |
|
980 |
968 |
$378K |
| 29827 |
|
188 |
188 |
$378K |
| 85610 |
|
130,595 |
121,023 |
$374K |
| 96401 |
|
5,241 |
3,329 |
$373K |
| 70491 |
|
2,715 |
2,693 |
$371K |
| 84403 |
|
16,637 |
16,297 |
$361K |
| 70486 |
|
4,242 |
4,212 |
$360K |
| 87340 |
|
69,683 |
68,970 |
$357K |
| 76825 |
|
1,810 |
1,648 |
$357K |
| 58558 |
|
282 |
282 |
$352K |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
8,935 |
8,897 |
$351K |
| T2022 |
Case management, per month |
4,216 |
2,684 |
$350K |
| D1110 |
Prophylaxis - adult |
7,828 |
6,077 |
$348K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
4,307 |
4,124 |
$347K |
| 29876 |
|
254 |
250 |
$343K |
| 0223U |
|
2,801 |
2,770 |
$339K |
| 86762 |
|
28,293 |
28,116 |
$338K |
| 12002 |
|
1,115 |
1,092 |
$337K |
| J1453 |
Injection, fosaprepitant, 1 mg |
4,129 |
2,826 |
$337K |
| 82784 |
|
25,134 |
22,481 |
$337K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
828 |
808 |
$330K |
| 52356 |
|
228 |
223 |
$327K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
831 |
648 |
$324K |
| 91322 |
|
4,057 |
4,054 |
$320K |
| 87563 |
|
13,751 |
13,559 |
$320K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
2,621 |
2,577 |
$316K |
| C1889 |
Implantable/insertable device, not otherwise classified |
2,196 |
2,188 |
$316K |
| 97010 |
|
19,886 |
8,202 |
$315K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
2,851 |
2,693 |
$313K |
| 99384 |
|
2,565 |
2,519 |
$312K |
| 70544 |
|
1,866 |
1,848 |
$310K |
| 87522 |
Neg quan hep c or qual rna |
8,022 |
7,772 |
$307K |
| 92133 |
|
4,346 |
4,145 |
$306K |
| 86765 |
|
28,795 |
28,609 |
$306K |
| 87486 |
|
5,735 |
5,636 |
$304K |
| 86923 |
|
5,603 |
4,983 |
$304K |
| 29888 |
|
118 |
118 |
$302K |
| 94060 |
|
4,930 |
4,542 |
$302K |
| 84702 |
|
83,188 |
75,241 |
$296K |
| 86706 |
|
39,855 |
39,492 |
$295K |
| 77338 |
|
1,155 |
915 |
$293K |
| J9070 |
Cyclophosphamide, 100 mg |
1,008 |
592 |
$291K |
| 97803 |
|
5,340 |
4,877 |
$290K |
| 20550 |
|
1,113 |
1,057 |
$289K |
| 11721 |
|
4,177 |
3,776 |
$288K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
2,660 |
2,337 |
$286K |
| 77280 |
|
994 |
832 |
$286K |
| 88341 |
|
4,192 |
4,081 |
$283K |
| 99402 |
|
4,285 |
3,536 |
$282K |
| 82746 |
|
32,110 |
31,843 |
$280K |
| 86317 |
|
1,007 |
822 |
$275K |
| 83735 |
|
138,273 |
118,820 |
$273K |
| 90734 |
|
14,297 |
14,213 |
$272K |
| 97802 |
|
4,344 |
4,325 |
$270K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
7,982 |
5,285 |
$269K |
| 81337 |
|
6,114 |
6,041 |
$268K |
| 80321 |
|
9,166 |
5,657 |
$266K |
| 95816 |
|
1,108 |
1,034 |
$265K |
| 94726 |
|
7,239 |
6,759 |
$263K |
| C1732 |
Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping |
262 |
261 |
$262K |
| 77062 |
|
3,403 |
3,390 |
$262K |
| 99382 |
|
1,928 |
1,925 |
$261K |
| 77385 |
|
1,164 |
117 |
$260K |
| 92526 |
|
1,920 |
1,392 |
$259K |
| 94010 |
|
7,977 |
7,419 |
$259K |
| 96417 |
|
5,380 |
3,766 |
$258K |
| 83540 |
|
79,768 |
77,725 |
$257K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
99,492 |
93,498 |
$256K |
| 96156 |
|
1,385 |
1,299 |
$256K |
| 76641 |
|
4,082 |
4,048 |
$255K |
| 26055 |
|
236 |
202 |
$254K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
75,157 |
47,302 |
$253K |
| 82570 |
|
75,733 |
72,775 |
$252K |
| 93971 |
|
3,516 |
3,475 |
$252K |
| 76801 |
|
3,356 |
3,055 |
$250K |
| 84402 |
|
11,519 |
11,378 |
$248K |
| 96409 |
|
2,906 |
1,633 |
$245K |
| 92579 |
|
4,281 |
4,235 |
$242K |
| 90633 |
|
16,277 |
16,201 |
$241K |
| 92555 |
|
3,211 |
3,187 |
$238K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
1,607 |
1,520 |
$238K |
| 81229 |
|
269 |
266 |
$237K |
| 93880 |
|
1,589 |
1,564 |
$233K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
6,676 |
4,083 |
$232K |
| 87517 |
|
5,205 |
5,070 |
$232K |
| 84207 |
|
9,127 |
9,058 |
$230K |
| 90680 |
|
18,414 |
18,404 |
$222K |
| 94729 |
|
7,641 |
7,133 |
$217K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
5,763 |
5,372 |
$216K |
| 84153 |
|
21,134 |
20,538 |
$215K |
| 92587 |
|
4,176 |
3,790 |
$213K |
| 76882 |
|
4,046 |
3,829 |
$212K |
| 11901 |
|
695 |
667 |
$209K |
| C1781 |
Mesh (implantable) |
1,138 |
1,130 |
$207K |
| 88304 |
|
5,550 |
5,485 |
$206K |
| 73562 |
|
11,562 |
11,161 |
$205K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
17,096 |
12,122 |
$205K |
| J3535 |
Drug administered through a metered dose inhaler |
8,382 |
7,919 |
$204K |
| 87902 |
|
738 |
717 |
$204K |
| J2785 |
Injection, regadenoson, 0.1 mg |
2,094 |
2,082 |
$203K |
| 51741 |
|
1,234 |
1,148 |
$203K |
| 81003 |
|
76,217 |
71,074 |
$200K |
| 93923 |
|
2,852 |
2,816 |
$199K |
| 83001 |
|
12,728 |
12,577 |
$197K |
| 95024 |
|
926 |
894 |
$196K |
| 81401 |
|
1,189 |
1,187 |
$196K |
| 49650 |
|
100 |
97 |
$196K |
| 77080 |
|
5,101 |
4,920 |
$195K |
| 84146 |
|
11,657 |
11,470 |
$195K |
| 76942 |
|
1,497 |
1,357 |
$195K |
| 46600 |
|
1,003 |
1,000 |
$193K |
| 87081 |
|
43,014 |
41,966 |
$192K |
| 72110 |
|
6,429 |
6,399 |
$192K |
| 70543 |
|
539 |
537 |
$186K |
| 55700 |
|
162 |
162 |
$186K |
| 90707 |
|
8,186 |
8,143 |
$186K |
| 92610 |
|
1,514 |
1,507 |
$184K |
| 80197 |
|
26,018 |
16,226 |
$183K |
| 77061 |
|
2,917 |
2,902 |
$183K |
| 93017 |
|
3,869 |
3,844 |
$182K |
| D0274 |
Bitewings - four radiographic images |
7,936 |
7,498 |
$181K |
| 88112 |
|
2,951 |
2,596 |
$181K |
| 96416 |
|
729 |
409 |
$181K |
| 82043 |
|
49,137 |
48,606 |
$180K |
| 73700 |
|
1,523 |
1,513 |
$179K |
| 76870 |
|
4,602 |
4,529 |
$176K |
| 90697 |
|
9,325 |
9,321 |
$175K |
| 58661 |
|
134 |
131 |
$175K |
| 84445 |
|
2,474 |
2,439 |
$174K |
| 86787 |
|
25,711 |
25,534 |
$174K |
| 85730 |
|
101,037 |
96,869 |
$172K |
| 99173 |
|
6,484 |
6,455 |
$172K |
| 96411 |
|
3,186 |
2,287 |
$171K |
| 72195 |
|
921 |
915 |
$169K |
| 76857 |
|
14,604 |
14,424 |
$169K |
| 73630 |
|
15,004 |
14,600 |
$168K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
236 |
235 |
$168K |
| D2392 |
Resin-based composite - two surfaces, posterior, primary or permanent |
2,698 |
2,422 |
$166K |
| 86161 |
|
10,969 |
10,672 |
$166K |
| 96402 |
|
2,705 |
2,587 |
$164K |
| 83516 |
|
11,211 |
11,091 |
$163K |
| 99188 |
|
3,033 |
3,031 |
$163K |
| 88360 |
|
1,806 |
1,757 |
$162K |
| 93975 |
|
862 |
853 |
$161K |
| 86704 |
|
21,622 |
21,369 |
$160K |
| 20680 |
|
100 |
97 |
$159K |
| 84100 |
|
90,318 |
77,634 |
$158K |
| 71271 |
|
2,233 |
2,209 |
$157K |
| C1760 |
Closure device, vascular (implantable/insertable) |
1,227 |
1,208 |
$157K |
| 69210 |
|
3,895 |
3,847 |
$156K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
4,315 |
4,254 |
$156K |
| 73030 |
|
12,499 |
12,065 |
$155K |
| 87077 |
|
35,507 |
34,574 |
$155K |
| 74240 |
|
1,906 |
1,897 |
$155K |
| 90999 |
Unlisted dialysis procedure, inpatient or outpatient |
688 |
168 |
$155K |
| 97165 |
|
1,391 |
1,388 |
$154K |
| 93351 |
|
1,296 |
1,284 |
$153K |
| 58100 |
|
478 |
475 |
$153K |
| 86902 |
|
1,037 |
951 |
$152K |
| 87088 |
|
34,593 |
33,524 |
$151K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
44,857 |
44,468 |
$150K |
| 72100 |
|
11,660 |
11,557 |
$150K |
| 78582 |
|
369 |
365 |
$148K |
| 86922 |
|
2,677 |
2,212 |
$147K |
| 84255 |
|
6,722 |
6,675 |
$147K |
| 77295 |
|
631 |
561 |
$144K |
| 99245 |
|
673 |
671 |
$143K |
| 99406 |
|
3,518 |
3,414 |
$143K |
| 83002 |
|
9,953 |
9,807 |
$143K |
| 41010 |
|
132 |
132 |
$142K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
2,316 |
2,252 |
$141K |
| 90656 |
|
10,951 |
10,853 |
$138K |
| G2068 |
Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
531 |
220 |
$137K |
| D2391 |
Resin-based composite - one surface, posterior, primary or permanent |
2,865 |
2,592 |
$136K |
| 82670 |
|
5,766 |
5,626 |
$136K |
| 72156 |
|
535 |
531 |
$135K |
| 97804 |
|
2,578 |
2,560 |
$135K |
| 87653 |
|
4,189 |
4,167 |
$134K |
| 84425 |
|
10,539 |
10,454 |
$134K |
| 31579 |
|
437 |
428 |
$134K |
| 57454 |
|
355 |
354 |
$134K |
| 90619 |
|
1,351 |
1,307 |
$134K |
| 72082 |
|
3,314 |
3,278 |
$133K |
| 73130 |
|
11,801 |
11,287 |
$133K |
| J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
86 |
77 |
$133K |
| 97163 |
|
936 |
931 |
$132K |
| 90716 |
|
7,331 |
7,298 |
$132K |
| 86235 |
|
7,509 |
7,275 |
$131K |
| 29125 |
|
861 |
851 |
$131K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
5,257 |
5,242 |
$131K |
| 72146 |
|
830 |
827 |
$130K |
| 81479 |
Unlisted molecular pathology procedure |
854 |
828 |
$129K |
| 42830 |
|
81 |
81 |
$129K |
| 90698 |
|
9,621 |
9,611 |
$128K |
| 86140 |
|
49,292 |
47,414 |
$127K |
| 87529 |
|
3,320 |
3,275 |
$127K |
| 93225 |
|
1,653 |
1,619 |
$126K |
| 74174 |
|
865 |
849 |
$126K |
| 72131 |
|
1,656 |
1,650 |
$126K |
| J9264 |
Injection, paclitaxel protein-bound particles, 1 mg |
75 |
25 |
$125K |
| 86735 |
|
16,995 |
16,921 |
$124K |
| 52310 |
|
113 |
113 |
$124K |
| 93886 |
|
410 |
388 |
$123K |
| 64400 |
|
333 |
256 |
$122K |
| 73610 |
|
12,137 |
11,577 |
$122K |
| 83615 |
|
38,957 |
31,093 |
$122K |
| D1330 |
|
6,599 |
5,007 |
$120K |
| 90849 |
|
1,203 |
594 |
$120K |
| 72158 |
|
452 |
448 |
$120K |
| 84446 |
|
10,014 |
9,933 |
$120K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
1,855 |
1,754 |
$119K |
| 73560 |
|
9,726 |
9,522 |
$118K |
| 90710 |
|
8,841 |
8,804 |
$118K |
| 51702 |
|
550 |
493 |
$117K |
| 83605 |
|
80,134 |
74,270 |
$117K |
| 82330 |
|
80,852 |
74,916 |
$117K |
| C1776 |
Joint device (implantable) |
26 |
26 |
$116K |
| 74160 |
|
1,071 |
1,063 |
$115K |
| 95913 |
|
987 |
898 |
$114K |
| 82948 |
|
53,630 |
46,636 |
$114K |
| 96112 |
|
851 |
838 |
$114K |
| 0003A |
|
3,061 |
3,057 |
$113K |
| 86021 |
|
5,595 |
5,230 |
$113K |
| 73200 |
|
1,026 |
1,017 |
$113K |
| 92552 |
|
1,182 |
1,168 |
$111K |
| 90746 |
|
2,676 |
2,656 |
$111K |
| 84597 |
|
9,239 |
9,173 |
$111K |
| 76775 |
|
3,641 |
3,625 |
$110K |
| D1208 |
Topical application of fluoride, excluding varnish |
7,251 |
6,892 |
$109K |
| 90381 |
|
313 |
312 |
$108K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
554 |
542 |
$108K |
| 76827 |
|
1,814 |
1,650 |
$108K |
| 83883 |
|
5,100 |
4,085 |
$107K |
| 73110 |
|
8,799 |
8,067 |
$107K |
| 87070 |
|
20,328 |
19,764 |
$106K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
21,865 |
21,695 |
$106K |
| 29848 |
|
53 |
52 |
$105K |
| P9035 |
Platelets, pheresis, leukocytes reduced, each unit |
243 |
119 |
$104K |
| 90648 |
|
7,120 |
7,103 |
$104K |
| 99397 |
|
950 |
945 |
$104K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
11,546 |
11,428 |
$103K |
| 82785 |
|
10,114 |
9,875 |
$102K |
| 84590 |
|
10,182 |
10,092 |
$101K |
| 75561 |
|
336 |
335 |
$101K |
| 97161 |
|
960 |
957 |
$101K |
| 90696 |
|
7,386 |
7,348 |
$99K |
| 87581 |
|
5,784 |
5,684 |
$99K |
| 83690 |
|
85,298 |
80,578 |
$98K |
| 0124A |
|
2,767 |
2,760 |
$97K |
| 82525 |
|
9,992 |
9,899 |
$96K |
| 76813 |
|
1,367 |
1,286 |
$96K |
| 90662 |
|
3,074 |
3,059 |
$95K |
| 82627 |
|
5,428 |
5,367 |
$95K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
110 |
110 |
$94K |
| 93505 |
|
60 |
50 |
$93K |
| 99407 |
|
1,893 |
1,747 |
$93K |
| 92136 |
|
936 |
930 |
$93K |
| 86708 |
|
10,403 |
10,335 |
$93K |
| 86355 |
|
2,278 |
2,180 |
$90K |
| 58301 |
|
655 |
650 |
$89K |
| 10005 |
|
492 |
486 |
$89K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
577 |
569 |
$89K |
| 84703 |
|
30,962 |
29,445 |
$88K |
| 86200 |
|
5,579 |
5,525 |
$88K |
| D0220 |
Intraoral - periapical first radiographic image |
8,439 |
8,022 |
$88K |
| H0033 |
Oral medication administration, direct observation |
2,453 |
355 |
$88K |
| 99232 |
Subsequent hospital care, per day, moderate complexity |
811 |
239 |
$87K |
| J1750 |
Injection, iron dextran, 50 mg |
494 |
465 |
$86K |
| J2704 |
Injection, propofol, 10 mg |
52,007 |
48,367 |
$86K |
| 92340 |
Fitting of spectacles, except for aphakia; monofocal |
933 |
926 |
$85K |
| 92235 |
|
442 |
431 |
$85K |
| 49591 |
|
54 |
54 |
$85K |
| 70547 |
|
566 |
560 |
$84K |
| 82610 |
|
6,086 |
5,062 |
$84K |
| 84156 |
|
34,371 |
31,796 |
$84K |
| 86376 |
|
7,601 |
7,551 |
$82K |
| 71045 |
Radiologic examination, chest; single view |
18,737 |
17,888 |
$82K |
| 90691 |
|
984 |
979 |
$82K |
| 73502 |
|
6,230 |
6,132 |
$82K |
| 82375 |
|
80,197 |
74,326 |
$82K |
| 82550 |
|
79,261 |
73,637 |
$82K |
| 76514 |
|
781 |
734 |
$81K |
| 77085 |
|
732 |
690 |
$81K |
| H0038 |
Self-help/peer services, per 15 minutes |
1,477 |
1,108 |
$81K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
2,831 |
2,806 |
$81K |
| 0071A |
|
2,344 |
2,333 |
$81K |
| 72040 |
|
4,642 |
4,612 |
$81K |
| 70496 |
|
757 |
753 |
$81K |
| 90620 |
|
1,588 |
1,584 |
$81K |
| 88108 |
|
2,085 |
2,000 |
$80K |
| 58300 |
|
603 |
599 |
$78K |
| 90723 |
|
5,087 |
5,079 |
$78K |
| 84432 |
|
3,737 |
3,683 |
$77K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
26,346 |
23,962 |
$77K |
| 87338 |
|
10,594 |
10,535 |
$76K |
| 17110 |
|
232 |
227 |
$76K |
| 88262 |
|
838 |
828 |
$75K |
| 82397 |
|
3,823 |
3,786 |
$75K |
| 84550 |
|
27,206 |
23,819 |
$74K |
| 87186 |
|
24,141 |
23,497 |
$74K |
| 96376 |
|
9,071 |
8,316 |
$73K |
| D0230 |
Intraoral - periapical each additional radiographic image |
7,052 |
7,029 |
$71K |
| 93226 |
|
1,222 |
1,199 |
$71K |
| 86870 |
|
2,919 |
2,713 |
$71K |
| 88184 |
|
2,586 |
2,204 |
$71K |
| 87400 |
|
3,721 |
2,721 |
$71K |
| 70498 |
|
478 |
474 |
$71K |
| 19281 |
|
80 |
80 |
$70K |
| 74230 |
|
1,168 |
1,164 |
$70K |
| 81382 |
|
247 |
243 |
$70K |
| 97022 |
|
2,239 |
1,092 |
$70K |
| 11982 |
|
203 |
203 |
$70K |
| 83498 |
|
3,228 |
3,193 |
$69K |
| 84484 |
|
70,514 |
64,440 |
$68K |
| 90480 |
|
2,147 |
2,147 |
$68K |
| 70480 |
|
633 |
632 |
$68K |
| 80069 |
|
8,716 |
7,977 |
$68K |
| 90700 |
|
5,555 |
5,541 |
$67K |
| 11981 |
|
223 |
222 |
$67K |
| 84630 |
|
10,722 |
10,644 |
$67K |
| 93246 |
|
1,140 |
1,135 |
$66K |
| 82951 |
|
9,062 |
9,019 |
$66K |
| 81206 |
|
571 |
514 |
$66K |
| 82652 |
|
1,824 |
1,797 |
$66K |
| C1726 |
Catheter, balloon dilatation, non-vascular |
489 |
461 |
$66K |
| 93613 |
|
105 |
105 |
$65K |
| 99459 |
|
2,598 |
2,582 |
$64K |
| J1631 |
Injection, haloperidol decanoate, per 50 mg |
2,467 |
1,639 |
$64K |
| 86695 |
|
3,066 |
3,034 |
$64K |
| 76886 |
|
909 |
892 |
$64K |
| V2788 |
Presbyopia correcting function of intraocular lens |
872 |
206 |
$64K |
| 72050 |
|
2,124 |
2,118 |
$64K |
| 97166 |
|
516 |
515 |
$64K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
2,175 |
1,588 |
$64K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
74,725 |
67,735 |
$62K |
| 85245 |
|
2,340 |
2,298 |
$62K |
| 93242 |
|
637 |
636 |
$61K |
| 83550 |
|
16,951 |
16,536 |
$61K |
| 82378 |
|
4,716 |
3,988 |
$60K |
| 95811 |
|
119 |
109 |
$60K |
| 90378 |
|
166 |
138 |
$59K |
| 29515 |
|
360 |
359 |
$58K |
| 90744 |
|
3,921 |
3,905 |
$58K |
| 86038 |
|
13,904 |
13,787 |
$58K |
| 77373 |
|
81 |
29 |
$57K |
| 87147 |
|
10,116 |
9,918 |
$57K |
| 82157 |
|
2,501 |
2,477 |
$57K |
| 92582 |
|
645 |
639 |
$57K |
| 84154 |
|
5,134 |
5,077 |
$57K |
| 64405 |
|
324 |
269 |
$57K |
| 30520 |
|
83 |
83 |
$57K |
| 73521 |
|
3,015 |
2,990 |
$56K |
| 92020 |
|
617 |
614 |
$56K |
| 97116 |
|
2,098 |
1,332 |
$56K |
| 82565 |
|
22,874 |
22,432 |
$56K |
| 93248 |
|
705 |
702 |
$55K |
| 86682 |
|
3,899 |
3,827 |
$55K |
| A4648 |
Tissue marker, implantable, any type, each |
492 |
484 |
$55K |
| 82533 |
|
4,306 |
3,915 |
$55K |
| 86696 |
|
4,804 |
4,758 |
$55K |
| 88173 |
|
2,071 |
1,948 |
$55K |
| 82105 |
|
9,260 |
8,900 |
$55K |
| 74018 |
|
4,798 |
4,637 |
$54K |
| 86592 |
|
9,533 |
9,298 |
$54K |
| 11056 |
|
242 |
234 |
$54K |
| 86335 |
|
2,151 |
2,104 |
$54K |
| G0475 |
Hiv antigen/antibody, combination assay, screening |
2,903 |
2,862 |
$54K |
| 64635 |
|
82 |
69 |
$53K |
| 85246 |
|
3,427 |
3,342 |
$53K |
| 74221 |
|
1,073 |
1,065 |
$53K |
| A6410 |
Eye pad, sterile, each |
1,652 |
1,171 |
$52K |
| D9239 |
|
476 |
71 |
$52K |
| 82088 |
|
1,339 |
1,304 |
$52K |
| 85652 |
|
40,828 |
39,346 |
$52K |
| J8501 |
Aprepitant, oral, 5 mg |
3,274 |
3,243 |
$51K |
| 0012A |
|
1,432 |
1,430 |
$51K |
| 93978 |
|
466 |
465 |
$51K |
| 0072A |
|
1,290 |
1,288 |
$51K |
| 96160 |
|
1,168 |
1,156 |
$51K |
| J9045 |
Injection, carboplatin, 50 mg |
1,896 |
1,381 |
$51K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
2,104 |
852 |
$51K |
| 91200 |
|
2,350 |
2,333 |
$50K |
| 51600 |
|
76 |
74 |
$50K |
| 95885 |
|
987 |
912 |
$50K |
| 86147 |
|
3,193 |
3,146 |
$49K |
| D1206 |
Topical application of fluoride varnish |
1,640 |
1,632 |
$49K |
| 96167 |
|
1,089 |
959 |
$49K |
| 69200 |
|
845 |
784 |
$49K |
| 72070 |
|
3,259 |
3,244 |
$49K |
| 90717 |
|
382 |
381 |
$48K |
| 86304 |
|
3,273 |
2,635 |
$48K |
| 73564 |
|
1,911 |
1,839 |
$48K |
| 86255 |
|
3,301 |
3,047 |
$48K |
| 93798 |
|
1,183 |
202 |
$47K |
| 99223 |
Prolong inpt eval add15 m |
175 |
164 |
$47K |
| D0272 |
Bitewings - two radiographic images |
3,433 |
3,384 |
$47K |
| 86357 |
|
2,289 |
2,191 |
$47K |
| 84480 |
|
9,772 |
9,433 |
$46K |
| 87205 |
|
21,725 |
21,100 |
$46K |
| 82180 |
|
5,459 |
5,433 |
$46K |
| 94618 |
|
1,759 |
1,600 |
$45K |
| 86334 |
|
3,346 |
3,142 |
$45K |
| 88275 |
|
278 |
271 |
$45K |
| 86800 |
|
4,453 |
4,401 |
$45K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
4,570 |
4,377 |
$45K |
| J9267 |
Injection, paclitaxel, 1 mg |
2,545 |
1,189 |
$45K |
| 73140 |
|
4,299 |
4,051 |
$44K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
9,158 |
8,646 |
$44K |
| 73590 |
|
5,141 |
4,929 |
$44K |
| 95886 |
|
653 |
595 |
$44K |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
398 |
373 |
$44K |
| 88300 |
|
2,690 |
2,643 |
$44K |
| 84270 |
|
1,700 |
1,686 |
$44K |
| 0011A |
|
1,661 |
1,660 |
$43K |
| 29826 |
|
139 |
139 |
$43K |
| C1753 |
Catheter, intravascular ultrasound |
119 |
116 |
$43K |
| 59841 |
|
50 |
50 |
$43K |
| 82800 |
|
67,560 |
62,739 |
$43K |
| C1759 |
Catheter, intracardiac echocardiography |
98 |
97 |
$43K |
| 82977 |
|
13,547 |
12,419 |
$43K |
| 86945 |
|
1,555 |
1,074 |
$43K |
| 73522 |
|
1,400 |
1,387 |
$43K |
| 86225 |
|
10,993 |
10,751 |
$42K |
| 90678 |
|
249 |
249 |
$42K |
| 81257 |
|
485 |
484 |
$42K |
| D1354 |
|
2,304 |
734 |
$41K |
| D0330 |
Panoramic radiographic image |
1,394 |
1,376 |
$41K |
| 83993 |
|
3,931 |
3,878 |
$40K |
| 86812 |
|
898 |
887 |
$40K |
| 98968 |
|
784 |
671 |
$40K |
| 83921 |
|
2,944 |
2,908 |
$40K |
| 86618 |
|
3,293 |
3,274 |
$39K |
| 73080 |
|
4,579 |
4,253 |
$39K |
| 54150 |
|
37 |
36 |
$39K |
| 82542 |
|
2,433 |
2,375 |
$38K |
| 90647 |
|
2,399 |
2,398 |
$37K |
| 90375 |
|
12 |
12 |
$37K |
| J7050 |
Infusion, normal saline solution, 250 cc |
64,643 |
41,752 |
$37K |
| 82164 |
|
2,175 |
2,151 |
$37K |
| 84244 |
|
1,545 |
1,509 |
$37K |
| 86431 |
|
10,068 |
9,996 |
$37K |
| 0742T |
|
180 |
176 |
$37K |
| 94760 |
|
6,774 |
6,383 |
$37K |
| 88271 |
|
655 |
640 |
$36K |
| J1756 |
Injection, iron sucrose, 1 mg |
1,182 |
548 |
$36K |
| 72157 |
|
149 |
148 |
$36K |
| 92082 |
|
266 |
254 |
$36K |
| 82024 |
|
946 |
896 |
$36K |
| 88312 |
|
1,757 |
1,735 |
$35K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
42,575 |
40,557 |
$35K |
| 64721 |
|
43 |
40 |
$35K |
| 88237 |
|
220 |
215 |
$35K |
| 86880 |
|
2,624 |
2,438 |
$35K |
| 82247 |
|
5,331 |
3,783 |
$35K |
| 30420 |
|
12 |
12 |
$34K |
| 92285 |
|
432 |
411 |
$34K |
| 51728 |
|
88 |
87 |
$34K |
| 84305 |
|
2,293 |
2,266 |
$34K |
| 10061 |
|
174 |
171 |
$34K |
| 92611 |
|
380 |
334 |
$34K |
| 82947 |
|
91,530 |
85,547 |
$34K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
339 |
337 |
$34K |
| 96900 |
|
1,167 |
267 |
$34K |
| 73720 |
|
96 |
96 |
$34K |
| 91321 |
|
838 |
838 |
$33K |
| 92025 |
|
265 |
256 |
$33K |
| 76981 |
|
470 |
466 |
$33K |
| 97164 |
|
433 |
426 |
$33K |
| 90675 |
|
320 |
175 |
$33K |
| C1874 |
Stent, coated/covered, with delivery system |
28 |
28 |
$33K |
| J0178 |
Injection, aflibercept, 1 mg |
34 |
25 |
$33K |
| 92060 |
|
386 |
355 |
$33K |
| 86141 |
|
4,488 |
4,362 |
$33K |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
14,671 |
14,523 |
$32K |
| 83050 |
|
80,127 |
74,265 |
$32K |
| 88313 |
|
2,738 |
2,691 |
$32K |
| 86008 |
|
1,623 |
1,571 |
$32K |
| 86146 |
|
3,002 |
2,862 |
$32K |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
635 |
603 |
$31K |
| 0064A |
|
984 |
975 |
$31K |
| 77072 |
|
2,056 |
2,036 |
$31K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
575 |
573 |
$31K |
| D7140 |
Extraction, erupted tooth or exposed root |
596 |
436 |
$31K |
| 77073 |
|
1,390 |
1,379 |
$31K |
| 90632 |
|
542 |
539 |
$31K |
| 71270 |
|
174 |
170 |
$30K |
| 82150 |
|
26,786 |
25,613 |
$30K |
| 85046 |
|
20,995 |
18,289 |
$30K |
| 92250 |
|
398 |
369 |
$30K |
| D9997 |
|
646 |
301 |
$30K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
764 |
447 |
$30K |
| D0210 |
Intraoral - complete series of radiographic images |
3,615 |
3,590 |
$29K |
| 83519 |
|
1,209 |
1,187 |
$29K |
| 84144 |
|
1,569 |
1,460 |
$28K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
505 |
318 |
$28K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
41,906 |
37,086 |
$28K |
| 81207 |
|
232 |
217 |
$28K |
| J0882 |
Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) |
652 |
138 |
$28K |
| 82672 |
|
1,536 |
1,525 |
$28K |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
935 |
923 |
$28K |
| 99233 |
Prolong inpt eval add15 m |
217 |
64 |
$28K |
| 84681 |
|
1,811 |
1,786 |
$28K |
| 15830 |
|
13 |
12 |
$28K |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
460 |
437 |
$28K |
| 86665 |
|
2,289 |
2,219 |
$28K |
| 85240 |
|
2,489 |
2,439 |
$27K |
| A4314 |
Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) |
2,100 |
2,021 |
$27K |
| 0296T |
|
471 |
471 |
$27K |
| J1741 |
Injection, ibuprofen, 100 mg |
4,796 |
4,749 |
$27K |
| 95912 |
|
214 |
185 |
$27K |
| 36561 |
|
26 |
25 |
$27K |
| 86849 |
|
2,753 |
2,594 |
$27K |
| 84295 |
|
88,534 |
82,626 |
$27K |
| 93244 |
|
391 |
391 |
$27K |
| 73552 |
|
2,423 |
2,362 |
$27K |
| 87040 |
|
9,277 |
8,945 |
$26K |
| 95911 |
|
254 |
224 |
$26K |
| 86777 |
|
1,647 |
1,624 |
$26K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
12,498 |
10,477 |
$26K |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
2,959 |
2,615 |
$26K |
| 74019 |
|
5,314 |
5,221 |
$26K |
| 90677 |
|
151 |
151 |
$25K |
| 0134A |
|
734 |
733 |
$25K |
| 84155 |
|
11,252 |
10,036 |
$25K |
| J9171 |
Injection, docetaxel, 1 mg |
268 |
201 |
$25K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
1,121 |
665 |
$24K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
48,369 |
40,849 |
$24K |
| C1764 |
Event recorder, cardiac (implantable) |
91 |
91 |
$24K |
| 98960 |
|
1,303 |
1,201 |
$24K |
| 93280 |
|
374 |
341 |
$24K |
| D9310 |
|
509 |
309 |
$24K |
| P9037 |
Platelets, pheresis, leukocytes reduced, irradiated, each unit |
50 |
27 |
$24K |
| 84520 |
|
18,428 |
17,710 |
$24K |
| 86325 |
|
515 |
496 |
$23K |
| 84436 |
|
6,698 |
6,511 |
$23K |
| 96368 |
|
1,233 |
1,017 |
$23K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
174 |
171 |
$23K |
| 86644 |
|
2,203 |
2,179 |
$23K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
37,717 |
36,669 |
$23K |
| 86301 |
|
2,264 |
1,792 |
$23K |
| 74455 |
|
71 |
69 |
$23K |
| 90785 |
|
1,665 |
1,424 |
$23K |
| 82085 |
|
1,791 |
1,721 |
$23K |
| C1758 |
Catheter, ureteral |
1,322 |
1,291 |
$23K |
| 28296 |
|
12 |
12 |
$23K |
| 19081 |
|
12 |
12 |
$23K |
| 92524 |
|
153 |
153 |
$23K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
625 |
619 |
$23K |
| 72081 |
|
848 |
836 |
$23K |
| D0160 |
|
327 |
164 |
$22K |
| 90380 |
|
95 |
95 |
$22K |
| 83521 |
|
2,726 |
2,004 |
$22K |
| 29130 |
|
147 |
146 |
$22K |
| 83695 |
|
2,342 |
2,330 |
$21K |
| 12013 |
|
76 |
76 |
$21K |
| J9206 |
Injection, irinotecan, 20 mg |
1,096 |
401 |
$21K |
| 84132 |
|
72,503 |
67,884 |
$21K |
| 82310 |
|
13,446 |
12,904 |
$21K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
36,511 |
34,101 |
$21K |
| 86593 |
|
3,873 |
3,792 |
$20K |
| 62321 |
|
14 |
14 |
$20K |
| 96450 |
|
37 |
26 |
$20K |
| A9581 |
Injection, gadoxetate disodium, 1 ml |
324 |
321 |
$20K |
| 54640 |
|
15 |
15 |
$20K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
15 |
13 |
$20K |
| 73090 |
|
3,466 |
3,222 |
$20K |
| 51797 |
|
75 |
74 |
$20K |
| 82657 |
|
866 |
857 |
$20K |
| 72170 |
|
2,072 |
2,046 |
$19K |
| 29879 |
|
29 |
29 |
$19K |
| 49652 |
|
12 |
12 |
$19K |
| 88230 |
|
390 |
388 |
$19K |
| 96377 |
|
1,344 |
1,043 |
$19K |
| 80164 |
|
2,922 |
2,809 |
$19K |
| A6402 |
Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
1,301 |
1,290 |
$19K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
4,510 |
4,435 |
$19K |
| 81270 |
|
390 |
380 |
$18K |
| 81596 |
|
510 |
505 |
$18K |
| 64494 |
|
959 |
899 |
$18K |
| 82950 |
|
4,074 |
4,051 |
$18K |
| 71101 |
|
2,227 |
2,204 |
$18K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,826 |
1,703 |
$18K |
| 85044 |
|
17,002 |
14,940 |
$18K |
| 82248 |
|
5,262 |
3,762 |
$18K |
| 70360 |
|
1,507 |
1,491 |
$18K |
| 83010 |
|
2,102 |
1,887 |
$18K |
| 64450 |
|
111 |
94 |
$18K |
| J0592 |
Injection, buprenorphine hydrochloride, 0.1 mg |
1,217 |
138 |
$18K |
| 20552 |
|
101 |
80 |
$18K |
| 66982 |
|
12 |
12 |
$18K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
2,990 |
2,594 |
$18K |
| 83090 |
|
1,393 |
1,381 |
$18K |
| 85613 |
|
2,764 |
2,737 |
$17K |
| 83525 |
|
1,863 |
1,849 |
$17K |
| J9370 |
Vincristine sulfate, 1 mg |
1,914 |
1,253 |
$17K |
| 93990 |
|
339 |
327 |
$17K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
6,319 |
6,174 |
$17K |
| 93282 |
|
182 |
174 |
$17K |
| 76098 |
|
94 |
82 |
$17K |
| 17250 |
|
75 |
70 |
$17K |
| 73060 |
|
2,147 |
2,074 |
$17K |
| 87530 |
|
344 |
341 |
$16K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
688 |
285 |
$16K |
| 86039 |
|
4,379 |
4,327 |
$16K |
| 85247 |
|
1,208 |
1,180 |
$16K |
| 96158 |
|
220 |
180 |
$16K |
| J9190 |
Injection, fluorouracil, 500 mg |
1,190 |
651 |
$16K |
| J2680 |
Injection, fluphenazine decanoate, up to 25 mg |
597 |
243 |
$16K |
| 92556 |
|
321 |
321 |
$16K |
| 97168 |
|
259 |
246 |
$16K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
844 |
593 |
$16K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
17,891 |
17,523 |
$15K |
| D0140 |
Limited oral evaluation - problem focused |
1,412 |
1,386 |
$15K |
| 78264 |
|
72 |
71 |
$15K |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
524 |
300 |
$15K |
| 52332 |
|
13 |
12 |
$15K |
| 70490 |
|
89 |
89 |
$15K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
410 |
385 |
$15K |
| 74246 |
|
220 |
220 |
$15K |
| 85384 |
|
3,962 |
3,623 |
$15K |
| 80349 |
|
2,141 |
1,342 |
$15K |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
4,498 |
4,405 |
$15K |
| 96116 |
|
170 |
169 |
$15K |
| 51784 |
|
438 |
375 |
$15K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
388 |
386 |
$15K |
| 82677 |
|
1,042 |
1,036 |
$15K |
| 86162 |
|
1,217 |
1,139 |
$15K |
| 73718 |
|
61 |
61 |
$14K |
| 15853 |
|
760 |
752 |
$14K |
| 11402 |
|
12 |
12 |
$14K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
1,445 |
1,265 |
$14K |
| 36224 |
|
12 |
12 |
$14K |
| 84481 |
|
2,641 |
2,505 |
$14K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
391 |
26 |
$14K |
| 88346 |
|
273 |
270 |
$14K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
2,521 |
2,506 |
$14K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
5,606 |
5,529 |
$14K |
| 77370 |
|
64 |
62 |
$14K |
| 92508 |
Group treatment of speech, language, voice, communication, and/or auditory processing disorder |
521 |
255 |
$14K |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
73 |
72 |
$14K |
| 96113 |
|
131 |
129 |
$14K |
| 94645 |
|
1,118 |
1,083 |
$14K |
| 90681 |
|
1,045 |
1,044 |
$13K |
| 90713 |
|
886 |
881 |
$13K |
| 86341 |
|
993 |
966 |
$13K |
| 82787 |
|
1,167 |
1,071 |
$13K |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
6,024 |
5,956 |
$13K |
| 93312 |
|
41 |
41 |
$13K |
| 97760 |
|
172 |
140 |
$13K |
| 85362 |
|
9,902 |
9,687 |
$13K |
| 80180 |
|
1,702 |
1,568 |
$13K |
| 29405 |
|
56 |
51 |
$13K |
| 94664 |
|
1,494 |
1,468 |
$12K |
| 82390 |
|
2,108 |
2,089 |
$12K |
| G0008 |
Administration of influenza virus vaccine |
1,393 |
1,385 |
$12K |
| G2077 |
Periodic assessment; assessing periodically by an otp practitioner and includes a review of moud dosing, treatment response, other substance use disorder treatment needs, responses and patient-identified goals, and other relevant physical, nutrition and psychiatric treatment needs and goals; may be informed by administration of a standardized, evidence-based assessment, or the need and interest for harm reduction interventions and recovery support services (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to each primary code |
180 |
159 |
$12K |
| 72052 |
|
357 |
356 |
$12K |
| 87177 |
|
1,562 |
1,453 |
$12K |
| 67228 |
|
29 |
24 |
$12K |
| 85660 |
|
2,166 |
2,155 |
$12K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
12,561 |
10,990 |
$12K |
| 96523 |
|
255 |
243 |
$12K |
| 0154A |
|
343 |
342 |
$12K |
| 0051A |
|
324 |
323 |
$12K |
| 82668 |
|
1,056 |
1,024 |
$12K |
| 98967 |
|
251 |
212 |
$12K |
| 84134 |
|
1,902 |
1,862 |
$12K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
44,255 |
41,899 |
$12K |
| D2930 |
Prefabricated stainless steel crown - primary tooth |
103 |
95 |
$12K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
5,501 |
5,375 |
$11K |
| 86645 |
|
1,950 |
1,934 |
$11K |
| 89051 |
|
1,779 |
1,572 |
$11K |
| 82270 |
|
2,914 |
2,863 |
$11K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
1,892 |
1,704 |
$11K |
| 87634 |
|
2,804 |
2,749 |
$11K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
56,582 |
51,222 |
$11K |
| 92523 |
|
53 |
53 |
$11K |
| 27096 |
|
42 |
38 |
$11K |
| 82465 |
|
3,922 |
3,898 |
$11K |
| 95180 |
|
38 |
35 |
$11K |
| J0401 |
Injection, aripiprazole (abilify maintena), 1 mg |
46 |
27 |
$11K |
| 51705 |
|
53 |
50 |
$11K |
| 83835 |
|
773 |
715 |
$11K |
| 82374 |
|
10,663 |
10,529 |
$11K |
| 85651 |
|
9,017 |
8,660 |
$10K |
| 97597 |
|
55 |
47 |
$10K |
| 96154 |
|
436 |
414 |
$10K |
| 64644 |
|
31 |
31 |
$10K |
| 82274 |
|
2,779 |
2,770 |
$10K |
| D9430 |
|
134 |
82 |
$10K |
| 24640 |
|
29 |
26 |
$10K |
| 85380 |
|
645 |
644 |
$10K |
| 76377 |
|
187 |
186 |
$10K |
| 72128 |
|
160 |
160 |
$10K |
| 80323 |
|
2,100 |
2,048 |
$10K |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
161 |
154 |
$10K |
| 87593 |
|
95 |
90 |
$10K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
8,582 |
5,310 |
$10K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
2,567 |
2,368 |
$9K |
| D9230 |
Inhalation of nitrous oxide / analgesia, anxiolysis |
1,088 |
986 |
$9K |
| 80178 |
|
1,817 |
1,706 |
$9K |
| 70487 |
|
70 |
69 |
$9K |
| 52287 |
|
12 |
12 |
$9K |
| 93270 |
|
119 |
118 |
$9K |
| 90685 |
|
549 |
549 |
$9K |
| 95807 |
|
13 |
13 |
$9K |
| 73000 |
|
721 |
683 |
$9K |
| 20605 |
|
38 |
37 |
$9K |
| 86709 |
|
1,151 |
1,139 |
$9K |
| 93656 |
|
13 |
13 |
$9K |
| 11102 |
|
14 |
12 |
$9K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
22,280 |
18,035 |
$9K |
| 80354 |
|
201 |
189 |
$9K |
| 87449 |
|
2,774 |
2,460 |
$8K |
| 86403 |
|
1,831 |
1,811 |
$8K |
| D9110 |
|
586 |
580 |
$8K |
| 82103 |
|
888 |
878 |
$8K |
| 95018 |
|
46 |
45 |
$8K |
| 78306 |
|
71 |
64 |
$8K |
| 11104 |
|
13 |
12 |
$8K |
| 86705 |
|
1,470 |
1,447 |
$8K |
| 86774 |
|
589 |
583 |
$8K |
| 20526 |
|
36 |
36 |
$8K |
| 87075 |
|
2,338 |
2,254 |
$8K |
| 86778 |
|
677 |
665 |
$8K |
| 43762 |
|
72 |
69 |
$8K |
| 29505 |
|
56 |
55 |
$8K |
| 92550 |
|
125 |
125 |
$8K |
| 80177 |
|
1,860 |
1,773 |
$8K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
12,043 |
11,451 |
$8K |
| 96161 |
|
161 |
160 |
$8K |
| 95028 |
|
28 |
27 |
$8K |
| 99195 |
|
166 |
135 |
$8K |
| 82960 |
|
2,765 |
2,749 |
$8K |
| 86905 |
|
291 |
290 |
$7K |
| 88311 |
|
645 |
636 |
$7K |
| 80361 |
|
556 |
513 |
$7K |
| 64413 |
|
14 |
12 |
$7K |
| 29075 |
|
27 |
27 |
$7K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
17 |
17 |
$7K |
| 80156 |
|
1,087 |
1,056 |
$7K |
| C8930 |
Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision |
15 |
15 |
$7K |
| 77049 |
|
25 |
25 |
$7K |
| 72220 |
|
669 |
665 |
$7K |
| 99454 |
|
113 |
111 |
$7K |
| 11730 |
|
39 |
39 |
$7K |
| J9250 |
Methotrexate sodium, 5 mg |
2,487 |
1,072 |
$7K |
| J9046 |
Injection, bortezomib (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg |
470 |
120 |
$7K |
| 85018 |
|
1,154 |
1,052 |
$7K |
| 11100 |
|
12 |
12 |
$7K |
| 97167 |
|
50 |
50 |
$7K |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
572 |
559 |
$7K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
6,347 |
5,319 |
$7K |
| 96150 |
|
194 |
184 |
$7K |
| 87209 |
|
864 |
804 |
$7K |
| 80230 |
|
722 |
695 |
$7K |
| J1626 |
Injection, granisetron hydrochloride, 100 mcg |
2,173 |
1,046 |
$7K |
| 86747 |
|
379 |
374 |
$7K |
| 84238 |
|
208 |
208 |
$7K |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
229 |
224 |
$7K |
| 80329 |
|
1,283 |
1,236 |
$7K |
| 90714 |
|
278 |
278 |
$7K |
| 31624 |
|
12 |
12 |
$7K |
| 29065 |
|
28 |
27 |
$7K |
| 92978 |
|
40 |
39 |
$6K |
| P9100 |
Pathogen(s) test for platelets |
181 |
83 |
$6K |
| 86160 |
|
710 |
695 |
$6K |
| 20553 |
|
27 |
24 |
$6K |
| D2393 |
Resin-based composite - three surfaces, posterior, primary or permanent |
115 |
111 |
$6K |
| J1644 |
Injection, heparin sodium, per 1000 units |
8,308 |
4,068 |
$6K |
| L8600 |
Implantable breast prosthesis, silicone or equal |
571 |
567 |
$6K |
| 10160 |
|
24 |
24 |
$6K |
| 97018 |
|
386 |
215 |
$6K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
6,423 |
5,439 |
$6K |
| 82523 |
|
612 |
598 |
$6K |
| 81403 |
|
63 |
61 |
$6K |
| 77470 |
|
73 |
70 |
$6K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
512 |
351 |
$6K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
2,174 |
1,935 |
$6K |
| 86920 |
|
66 |
65 |
$6K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
183 |
183 |
$6K |
| 81050 |
|
2,129 |
2,059 |
$6K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
6,925 |
6,818 |
$6K |
| 92201 |
|
80 |
79 |
$6K |
| 99417 |
Prolong home eval add 15m |
838 |
825 |
$6K |
| 82077 |
|
7,003 |
6,501 |
$6K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
21,100 |
19,937 |
$6K |
| 86060 |
|
1,513 |
1,500 |
$6K |
| 82575 |
|
1,076 |
1,067 |
$6K |
| 0173A |
|
144 |
142 |
$6K |
| 93985 |
|
39 |
38 |
$6K |
| 77332 |
|
18 |
16 |
$6K |
| 82239 |
|
575 |
526 |
$6K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
8,429 |
7,237 |
$6K |
| G2074 |
Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
354 |
248 |
$5K |
| 99242 |
|
38 |
38 |
$5K |
| 84145 |
|
1,220 |
1,197 |
$5K |
| 77075 |
|
52 |
52 |
$5K |
| 85347 |
|
693 |
682 |
$5K |
| 83020 |
|
603 |
576 |
$5K |
| 72193 |
|
24 |
24 |
$5K |
| 86580 |
|
1,033 |
987 |
$5K |
| 87324 |
|
1,343 |
1,307 |
$5K |
| 80348 |
|
788 |
651 |
$5K |
| 38222 |
|
13 |
12 |
$5K |
| 0053A |
|
128 |
127 |
$5K |
| 88302 |
|
589 |
575 |
$5K |
| 95012 |
|
140 |
138 |
$5K |
| 64484 |
|
26 |
26 |
$5K |
| 95800 |
|
85 |
77 |
$5K |
| 77002 |
|
95 |
94 |
$5K |
| 92553 |
|
64 |
64 |
$5K |
| 94644 |
|
1,838 |
1,785 |
$5K |
| 81370 |
|
103 |
102 |
$5K |
| 82435 |
|
10,682 |
10,548 |
$5K |
| 36000 |
|
136 |
132 |
$5K |
| 91312 |
|
1,405 |
1,403 |
$5K |
| 88143 |
|
202 |
199 |
$5K |
| 81376 |
|
130 |
129 |
$5K |
| 87350 |
|
678 |
659 |
$5K |
| A6223 |
Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing |
127 |
127 |
$5K |
| 83721 |
|
1,508 |
1,498 |
$5K |
| 84112 |
|
261 |
254 |
$5K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
4,138 |
3,649 |
$5K |
| 82232 |
|
546 |
464 |
$5K |
| 85305 |
|
369 |
361 |
$4K |
| C2639 |
Brachytherapy source, non-stranded, iodine-125, per source |
27 |
27 |
$4K |
| 92520 |
|
54 |
53 |
$4K |
| 85097 |
|
73 |
70 |
$4K |
| 80195 |
|
634 |
416 |
$4K |
| 87210 |
|
1,067 |
1,003 |
$4K |
| 72083 |
|
113 |
111 |
$4K |
| J0694 |
Injection, cefoxitin sodium, 1 gm |
1,682 |
1,612 |
$4K |
| 82172 |
|
481 |
478 |
$4K |
| 90738 |
|
17 |
13 |
$4K |
| 85597 |
|
289 |
283 |
$4K |
| 93623 |
|
24 |
24 |
$4K |
| 82104 |
|
466 |
461 |
$4K |
| 86648 |
|
491 |
485 |
$4K |
| 81241 |
|
97 |
96 |
$4K |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
306 |
155 |
$4K |
| 80365 |
|
644 |
597 |
$4K |
| J0610 |
Injection, calcium gluconate (fresenius kabi), per 10 ml |
1,100 |
1,017 |
$4K |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
536 |
536 |
$4K |
| 74181 |
|
12 |
12 |
$4K |
| Q3014 |
Telehealth originating site facility fee |
148 |
141 |
$4K |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
225 |
165 |
$4K |
| 84075 |
|
1,485 |
1,456 |
$4K |
| 91010 |
|
37 |
37 |
$4K |
| 86701 |
|
552 |
534 |
$4K |
| 81364 |
|
13 |
12 |
$4K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
2,081 |
1,817 |
$4K |
| 99254 |
|
17 |
15 |
$4K |
| D1310 |
|
97 |
43 |
$4K |
| 91313 |
|
438 |
437 |
$4K |
| 85397 |
|
236 |
208 |
$4K |
| 73660 |
|
610 |
598 |
$4K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
4,255 |
4,173 |
$4K |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
4,498 |
4,066 |
$4K |
| 99457 |
|
91 |
91 |
$4K |
| C1730 |
Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) |
12 |
12 |
$3K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
475 |
396 |
$3K |
| 77001 |
|
12 |
12 |
$3K |
| 92511 |
|
126 |
125 |
$3K |
| 95910 |
|
51 |
41 |
$3K |
| 86340 |
|
365 |
359 |
$3K |
| A6258 |
Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing |
243 |
242 |
$3K |
| 92002 |
|
20 |
20 |
$3K |
| 82040 |
|
1,997 |
1,945 |
$3K |
| 99451 |
|
375 |
359 |
$3K |
| C1729 |
Catheter, drainage |
80 |
72 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
9,828 |
9,635 |
$3K |
| 86702 |
|
447 |
435 |
$3K |
| 80299 |
|
368 |
329 |
$3K |
| 73070 |
|
482 |
457 |
$3K |
| 76604 |
|
87 |
86 |
$3K |
| D2331 |
|
55 |
54 |
$3K |
| L3670 |
Shoulder orthosis, acromio/clavicular (canvas and webbing type), prefabricated, off-the-shelf |
1,180 |
1,175 |
$3K |
| 82985 |
|
553 |
548 |
$3K |
| 86336 |
|
515 |
512 |
$3K |
| A9567 |
Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries |
167 |
166 |
$3K |
| C1731 |
Catheter, electrophysiology, diagnostic, other than 3d mapping (20 or more electrodes) |
12 |
12 |
$3K |
| 99152 |
|
993 |
974 |
$3K |
| 77012 |
|
25 |
25 |
$3K |
| 97032 |
|
56 |
40 |
$3K |
| J1630 |
Injection, haloperidol, up to 5 mg |
3,196 |
2,686 |
$3K |
| 81240 |
|
66 |
65 |
$3K |
| 80158 |
|
450 |
297 |
$3K |
| J1953 |
Injection, levetiracetam, 10 mg |
530 |
466 |
$3K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
943 |
881 |
$3K |
| 87101 |
|
377 |
375 |
$3K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
520 |
505 |
$3K |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
1,220 |
1,142 |
$3K |
| D9920 |
|
165 |
150 |
$3K |
| 72202 |
|
108 |
104 |
$3K |
| 86707 |
|
301 |
298 |
$3K |
| 80143 |
|
2,754 |
2,655 |
$3K |
| 93662 |
|
67 |
67 |
$3K |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
2,583 |
2,572 |
$3K |
| 11055 |
|
12 |
12 |
$3K |
| 86300 |
|
221 |
215 |
$2K |
| 92342 |
|
26 |
25 |
$2K |
| 90658 |
|
186 |
186 |
$2K |
| 87184 |
|
945 |
933 |
$2K |
| 92588 |
|
81 |
77 |
$2K |
| 84300 |
|
792 |
762 |
$2K |
| 73223 |
|
13 |
13 |
$2K |
| 82010 |
|
3,018 |
2,917 |
$2K |
| 83030 |
|
1,063 |
1,018 |
$2K |
| J3489 |
Injection, zoledronic acid, 1 mg |
105 |
95 |
$2K |
| 0031A |
|
61 |
61 |
$2K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
50 |
50 |
$2K |
| 96040 |
|
25 |
25 |
$2K |
| 83992 |
|
109 |
100 |
$2K |
| 84460 |
|
812 |
808 |
$2K |
| 82626 |
|
125 |
125 |
$2K |
| J0612 |
Injection, calcium gluconate, not otherwise specified, 10 mg |
497 |
399 |
$2K |
| 80179 |
|
2,597 |
2,520 |
$2K |
| 85300 |
|
256 |
253 |
$2K |
| A6224 |
Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 48 sq. in., without adhesive border, each dressing |
301 |
300 |
$2K |
| 89320 |
|
214 |
207 |
$2K |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
728 |
719 |
$2K |
| 87116 |
|
421 |
397 |
$2K |
| 82955 |
|
313 |
312 |
$2K |
| 64643 |
|
12 |
12 |
$2K |
| 87102 |
|
455 |
431 |
$2K |
| 93308 |
|
14 |
14 |
$2K |
| J1815 |
Injection, insulin, per 5 units |
3,251 |
2,586 |
$2K |
| 86353 |
|
14 |
14 |
$2K |
| P9045 |
Infusion, albumin (human), 5%, 250 ml |
14 |
14 |
$2K |
| 86703 |
|
151 |
150 |
$2K |
| 64495 |
|
327 |
304 |
$2K |
| 80356 |
|
200 |
186 |
$2K |
| 76776 |
|
37 |
37 |
$2K |
| 85303 |
|
178 |
176 |
$2K |
| D0240 |
|
172 |
171 |
$2K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
12 |
12 |
$2K |
| C1766 |
Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away |
26 |
26 |
$2K |
| 95076 |
|
14 |
12 |
$2K |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
108 |
69 |
$2K |
| T1023 |
Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter |
46 |
46 |
$2K |
| 83935 |
|
415 |
387 |
$2K |
| 94727 |
|
62 |
49 |
$2K |
| 81002 |
|
3,131 |
2,866 |
$2K |
| 74170 |
|
12 |
12 |
$2K |
| 80358 |
|
256 |
229 |
$2K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
1,140 |
1,110 |
$2K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
10,375 |
9,182 |
$2K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
44 |
44 |
$2K |
| J7999 |
Compounded drug, not otherwise classified |
242 |
224 |
$2K |
| A5112 |
Urinary drainage bag, leg or abdomen, latex, with or without tube, with straps, each |
142 |
118 |
$2K |
| 95873 |
|
70 |
57 |
$2K |
| 90688 |
|
107 |
107 |
$2K |
| J3480 |
Injection, potassium chloride, per 2 meq |
1,986 |
1,156 |
$2K |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
14 |
14 |
$2K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
12 |
12 |
$2K |
| 86308 |
|
1,016 |
1,008 |
$2K |
| 96151 |
|
64 |
61 |
$2K |
| 96130 |
|
32 |
28 |
$2K |
| 93285 |
|
12 |
12 |
$2K |
| 85460 |
|
183 |
176 |
$1K |
| 81599 |
|
33 |
33 |
$1K |
| 82656 |
|
222 |
219 |
$1K |
| 99452 |
|
101 |
95 |
$1K |
| 96136 |
|
41 |
36 |
$1K |
| A6257 |
Transparent film, sterile, 16 sq. in. or less, each dressing |
145 |
145 |
$1K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
27 |
14 |
$1K |
| 73120 |
|
53 |
51 |
$1K |
| 85732 |
|
402 |
388 |
$1K |
| 75571 |
|
39 |
38 |
$1K |
| 99050 |
|
97 |
95 |
$1K |
| J7510 |
Prednisolone oral, per 5 mg |
3,964 |
3,891 |
$1K |
| 80175 |
|
171 |
169 |
$1K |
| 86784 |
|
179 |
178 |
$1K |
| G0009 |
Administration of pneumococcal vaccine |
170 |
167 |
$1K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
427 |
357 |
$1K |
| V5011 |
Fitting/orientation/checking of hearing aid |
13 |
13 |
$1K |
| 82952 |
|
900 |
897 |
$1K |
| D0270 |
|
210 |
209 |
$1K |
| 87305 |
|
284 |
177 |
$1K |
| 88368 |
|
12 |
12 |
$1K |
| 73620 |
|
58 |
57 |
$1K |
| 90672 |
|
120 |
120 |
$1K |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
903 |
851 |
$1K |
| 80320 |
|
3,253 |
3,041 |
$1K |
| 72084 |
|
22 |
22 |
$1K |
| 99153 |
Mod sedat endo service >5yrs |
525 |
514 |
$1K |
| 80162 |
|
212 |
163 |
$1K |
| S9441 |
Asthma education, non-physician provider, per session |
462 |
461 |
$1K |
| D2335 |
|
12 |
12 |
$1K |
| 80145 |
|
50 |
50 |
$1K |
| C9399 |
Unclassified drugs or biologicals |
53 |
43 |
$1K |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
855 |
842 |
$1K |
| 85027 |
|
647 |
602 |
$1K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
576 |
404 |
$1K |
| 76506 |
|
13 |
13 |
$984.00 |
| 87493 |
|
38 |
38 |
$955.33 |
| 80346 |
|
143 |
132 |
$949.97 |
| 93284 |
|
12 |
12 |
$945.70 |
| 98966 |
|
13 |
12 |
$927.69 |
| C9113 |
Injection, pantoprazole sodium, per vial |
601 |
528 |
$926.24 |
| J3411 |
Injection, thiamine hcl, 100 mg |
606 |
531 |
$911.30 |
| V2787 |
Astigmatism correcting function of intraocular lens |
32 |
28 |
$910.80 |
| J2060 |
Injection, lorazepam, 2 mg |
3,148 |
2,714 |
$907.12 |
| 76937 |
|
15 |
15 |
$899.48 |
| 81470 |
|
27 |
27 |
$895.72 |
| 90611 |
|
13 |
13 |
$887.01 |
| 74150 |
|
13 |
13 |
$871.00 |
| D0145 |
Oral evaluation for a patient under three years of age |
29 |
29 |
$870.00 |
| 0225U |
|
158 |
158 |
$868.12 |
| 82360 |
|
219 |
214 |
$863.54 |
| 97535 |
Self-care/home management training, each 15 minutes |
22 |
14 |
$834.96 |
| 86664 |
|
95 |
95 |
$830.91 |
| 84999 |
|
84 |
82 |
$827.15 |
| 84080 |
|
107 |
102 |
$814.87 |
| 90461 |
|
2,650 |
2,638 |
$810.15 |
| 71111 |
|
64 |
64 |
$806.95 |
| A4615 |
Cannula, nasal |
178 |
172 |
$797.90 |
| 73600 |
|
65 |
63 |
$796.96 |
| 86606 |
|
104 |
100 |
$795.66 |
| 90474 |
|
2,068 |
2,067 |
$794.70 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
1,577 |
1,575 |
$784.11 |
| 96131 |
|
23 |
20 |
$767.82 |
| 97750 |
|
27 |
26 |
$736.03 |
| 0054A |
|
17 |
16 |
$732.39 |
| G0117 |
Glaucoma screening for high risk patients furnished by an optometrist or ophthalmologist |
68 |
68 |
$723.43 |
| 77081 |
|
27 |
26 |
$698.54 |
| 87533 |
|
19 |
12 |
$694.53 |
| C1788 |
Port, indwelling (implantable) |
12 |
12 |
$693.60 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
20,487 |
19,809 |
$692.67 |
| 70030 |
|
26 |
26 |
$671.93 |
| 99292 |
|
15 |
15 |
$660.00 |
| 86256 |
|
83 |
78 |
$641.02 |
| J2598 |
Injection, vasopressin, 1 unit |
50 |
49 |
$640.79 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
421 |
403 |
$613.79 |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
14 |
14 |
$606.82 |
| 87015 |
|
326 |
308 |
$603.67 |
| 85007 |
|
649 |
604 |
$600.57 |
| 80353 |
|
71 |
68 |
$588.41 |
| 83718 |
|
338 |
338 |
$588.02 |
| 74175 |
|
12 |
12 |
$586.19 |
| 82140 |
|
205 |
199 |
$583.56 |
| 94799 |
|
989 |
971 |
$576.07 |
| 76820 |
|
18 |
12 |
$574.91 |
| 0013A |
|
15 |
15 |
$572.47 |
| 85598 |
|
58 |
57 |
$571.29 |
| 83930 |
|
164 |
158 |
$567.71 |
| 73100 |
|
54 |
51 |
$559.44 |
| 93352 |
|
26 |
26 |
$555.94 |
| 72114 |
|
15 |
15 |
$553.24 |
| 99458 |
|
13 |
13 |
$525.88 |
| 93288 |
|
18 |
15 |
$518.36 |
| 87206 |
|
316 |
296 |
$517.22 |
| 96137 |
|
25 |
23 |
$517.13 |
| 90674 |
|
19 |
19 |
$515.82 |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
60 |
58 |
$486.48 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
17,674 |
15,248 |
$475.85 |
| J3371 |
Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg |
112 |
112 |
$462.15 |
| 90660 |
|
32 |
32 |
$461.58 |
| 97124 |
|
21 |
12 |
$461.04 |
| 85520 |
|
45 |
30 |
$460.99 |
| J3360 |
Injection, diazepam, up to 5 mg |
232 |
187 |
$457.85 |
| 87046 |
|
228 |
223 |
$455.27 |
| 91315 |
|
148 |
148 |
$435.01 |
| 88141 |
|
13 |
13 |
$425.10 |
| J1940 |
Injection, furosemide, up to 20 mg |
788 |
702 |
$424.58 |
| 82810 |
|
283 |
274 |
$421.71 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
230 |
229 |
$419.41 |
| Q0245 |
Injection, bamlanivimab and etesevimab, 2100 mg |
87 |
57 |
$414.20 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
708 |
650 |
$399.15 |
| 93356 |
|
40 |
40 |
$393.75 |
| 82340 |
|
102 |
102 |
$384.66 |
| 80235 |
|
26 |
26 |
$341.68 |
| 88274 |
|
39 |
37 |
$334.01 |
| J0574 |
Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine |
308 |
55 |
$326.71 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
3,049 |
2,950 |
$318.32 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
226 |
209 |
$311.80 |
| J2720 |
Injection, protamine sulfate, per 10 mg |
182 |
181 |
$285.64 |
| 86337 |
|
28 |
28 |
$266.62 |
| 86663 |
|
26 |
26 |
$265.28 |
| L1832 |
Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
12 |
12 |
$258.26 |
| 80185 |
|
61 |
55 |
$253.37 |
| 86316 |
|
26 |
24 |
$253.20 |
| 82747 |
|
16 |
14 |
$248.18 |
| 84450 |
|
100 |
100 |
$247.95 |
| 84202 |
|
41 |
36 |
$220.89 |
| 61782 |
|
29 |
29 |
$211.36 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
182 |
182 |
$197.51 |
| J2305 |
Injection, nitroglycerin, 5 mg |
327 |
320 |
$191.30 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
79 |
79 |
$190.68 |
| A4333 |
Urinary catheter anchoring device, adhesive skin attachment, each |
174 |
155 |
$189.08 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
12 |
12 |
$187.20 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
359 |
346 |
$176.63 |
| J9260 |
Injection, methotrexate sodium, 50 mg |
56 |
42 |
$171.14 |
| 83789 |
|
14 |
13 |
$170.28 |
| 82945 |
|
98 |
91 |
$148.35 |
| 80500 |
|
26 |
25 |
$146.92 |
| J1250 |
Injection, dobutamine hydrochloride, per 250 mg |
14 |
14 |
$143.97 |
| 82962 |
|
852 |
820 |
$143.32 |
| 73551 |
|
39 |
39 |
$140.89 |
| 96373 |
|
12 |
12 |
$137.18 |
| 70250 |
|
13 |
13 |
$129.76 |
| 82705 |
|
42 |
40 |
$129.44 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
65 |
57 |
$128.86 |
| J2310 |
Injection, naloxone hydrochloride, per 1 mg |
13 |
12 |
$127.48 |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
89 |
89 |
$109.93 |
| Q0166 |
Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen |
22 |
12 |
$94.98 |
| S0028 |
Injection, famotidine, 20 mg |
62 |
40 |
$90.33 |
| OP250 |
|
76 |
50 |
$89.06 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
97 |
97 |
$88.27 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
96 |
96 |
$75.43 |
| 84482 |
|
13 |
13 |
$73.70 |
| J0613 |
Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg |
24 |
24 |
$71.92 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
139 |
135 |
$71.37 |
| 87045 |
|
14 |
14 |
$67.18 |
| 84157 |
|
38 |
38 |
$59.36 |
| 80183 |
|
13 |
13 |
$57.58 |
| A6203 |
Composite dressing, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing |
164 |
164 |
$52.71 |
| 87450 |
|
97 |
96 |
$51.82 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
710 |
708 |
$49.73 |
| 96159 |
|
15 |
13 |
$46.24 |
| 84478 |
|
129 |
121 |
$40.24 |
| 87899 |
|
24 |
24 |
$37.32 |
| J7121 |
5% dextrose in lactated ringers infusion, up to 1000 cc |
20 |
17 |
$35.08 |
| 80362 |
|
13 |
13 |
$35.00 |
| 89060 |
|
12 |
12 |
$31.14 |
| 76010 |
|
14 |
14 |
$28.51 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
117 |
98 |
$27.25 |
| 64636 |
|
72 |
65 |
$25.66 |
| A4357 |
Bedside drainage bag, day or night, with or without anti-reflux device, with or without tube, each |
15 |
13 |
$21.90 |
| A6222 |
Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
122 |
121 |
$18.54 |
| A6446 |
Conforming bandage, non-elastic, knitted/woven, sterile, width greater than or equal to three inches and less than five inches, per yard |
37 |
36 |
$15.81 |
| 82595 |
|
15 |
15 |
$14.25 |
| 85014 |
|
24 |
24 |
$12.41 |
| A6454 |
Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to three inches and less than five inches, per yard |
96 |
96 |
$10.75 |
| A4340 |
Indwelling catheter; specialty type, (e.g., coude, mushroom, wing, etc.), each |
13 |
12 |
$5.68 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
12 |
12 |
$5.28 |
| A4351 |
Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each |
51 |
51 |
$4.94 |
| A6403 |
Gauze, non-impregnated, sterile, pad size more than 16 sq. in. less than or equal to 48 sq. in., without adhesive border, each dressing |
73 |
73 |
$4.84 |
| 91300 |
|
72 |
72 |
$3.23 |
| J1071 |
Injection, testosterone cypionate, 1 mg |
52 |
36 |
$1.39 |
| A6252 |
Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing |
17 |
17 |
$1.30 |
| A6253 |
Specialty absorptive dressing, wound cover, sterile, pad size more than 48 sq. in., without adhesive border, each dressing |
72 |
71 |
$0.65 |
| A6445 |
Conforming bandage, non-elastic, knitted/woven, sterile, width less than three inches, per yard |
19 |
19 |
$0.41 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
44 |
30 |
$0.39 |
| Q0222 |
Injection, bebtelovimab, 175 mg |
52 |
52 |
$0.22 |
| J1836 |
Injection, metronidazole, 10 mg |
27 |
26 |
$0.18 |
| Q0239 |
Injection, bamlanivimab-xxxx, 700 mg |
58 |
58 |
$0.17 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
306 |
305 |
$0.06 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
43 |
40 |
$0.02 |
| D9999 |
Unspecified adjunctive procedure, by report |
264 |
256 |
$0.00 |
| D6999 |
|
142 |
125 |
$0.00 |
| 99429 |
|
9,367 |
6,514 |
$0.00 |
| D9215 |
|
515 |
480 |
$0.00 |
| D5899 |
|
390 |
308 |
$0.00 |
| D9630 |
|
412 |
412 |
$0.00 |
| S2900 |
Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) |
239 |
239 |
$0.00 |
| 99024 |
|
27 |
25 |
$0.00 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
14 |
13 |
$0.00 |
| D1320 |
|
15 |
15 |
$0.00 |
| A4338 |
Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each |
13 |
13 |
$0.00 |
| A9539 |
Technetium tc-99m pentetate, diagnostic, per study dose, up to 25 millicuries |
15 |
15 |
$0.00 |
| 99080 |
|
105,724 |
24,151 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
39 |
39 |
$0.00 |
| 99199 |
Unlisted special service, procedure or report |
407 |
346 |
$0.00 |
| 99499 |
|
800 |
441 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
39 |
39 |
$0.00 |